The PAM, or protospacer adjacent motif, provides a required sequence landmark next to the DNA region recognized by the guide RNA. A matching guide sequence is therefore not sufficient by itself: the appropriate PAM must also be present for nuclease targeting. This requirement constrains which genetic sites are eligible and where editing can occur.
Guide RNA and Cas9 contribute different parts of the targeting process. The guide RNA supplies sequence complementarity to the selected DNA, while Cas9 acts as the CRISPR-associated nuclease that cuts the DNA. Their coordination connects sequence recognition with strand cleavage, allowing researchers to direct a break toward a locus chosen for genetic investigation or modification.
The repair pathway strongly influences the resulting genetic change. Non-homologous end joining reconnects broken DNA ends and can be used when the goal is to disrupt a gene. Homology-directed repair instead uses a supplied template, supporting correction or other planned sequence modifications. Selecting the pathway therefore links the DNA break to the intended genetic outcome.
A CRISPR genome editing workflow begins by identifying a genetic sequence of interest and checking for a nearby PAM. Researchers then select a complementary guide RNA and compatible nuclease, define whether the goal is disruption, correction, or modification, and determine whether repair should rely on end joining or a supplied template. The planned repair outcome guides the experimental design.
By deliberately disrupting, correcting, or modifying selected genes, researchers can examine how those genes contribute to biological traits or disease-related processes. In genetics, the resulting changes support functional studies and disease modeling. Comparing the intended genetic alteration with its observed consequences helps connect a DNA sequence to gene function or a disease phenotype.
The same ability to make targeted genetic changes supports several areas of genetics. Researchers apply it to disease modeling, investigate potential treatments for genetic disease, and pursue crop improvement. These applications use controlled changes in DNA to test biological hypotheses, explore useful traits, or evaluate emerging therapeutic strategies.